Audits | Cardiovascular health

Clinical audit: An update on organ protection in T2D: focus on cardiorenal disease

EA hours: 1.5
MO hours: 4
RP hours: 1
Total hours: 6.5
knight in armour with shield and sword
On this page

    Activity aim

    This clinical audit activity presents latest evidence-based recommendations and PBS pathways for reducing cardiorenal risk in people with type 2 diabetes and comorbid cardiovascular disease, multiple cardiovascular risk factors and/or kidney disease. It also provides a practical framework for optimising the care of patients with T2D who are facing enhanced cardiorenal risk, using lifestyle and guideline-directed medical therapies. 

    Why take part in this program?

    • Conduct follow-up consultations with 5 patients who have type 2 diabetes and high cardiovascular risk, to review and optimise their management
    • Earn 6.5 CPD hours upon completion.

    Inclusion criteria

    Patients who are eligible for this clinical audit are adults who are:

    • Adults aged 18 years and older
    • Type 2 diabetes
    • Currently managed with metformin (with or without SU)
    • One or more of the following:
      • Established CVD
      • High risk of CVD
      • Aboriginal or Torres Strait Islander
    • Not currently undergoing concomitant PBS-subsidised treatment for diabetes with a SGLT2 inhibitor or a GLP-1 RA

    How long should it take?

    The program has been designed to take approximately 4-6 weeks to complete. This includes patient recall from your practice, patient consult and program evaluation.

    Tips to recruit patients

    Recruitment may occur:

    • Opportunistically as you consult appropriate patients as part of usual care.
    • By active recall.

    Learning outcomes

    On completion of this educational activity participants will be able to:
    Describe the impact of cardiovascular disease (CVD) in people with type 2 diabetes (T2D) and the interrelationship of cardiometabolic risk factors that can lead to adverse CV and kidney outcomes in people with diabetes
    Summarise international and Australian recommendations for patients who have T2D and CV risk, CV disease or chronic kidney disease.
    Examine recommendations for using SGLT2 inhibitors for cardiovascular risk reduction and to help prevent progression to end-organ damage in T2D, including latest updates in the 2024 Australian T2D management guidelines
    Incorporate latest changes to PBS restrictions for T2D medicines into your clinical practice.
    New clinical audit

    Boost your Measuring Outcomes CPD hours with this new clinical audit 

    Clinical audit: An update on organ protection in T2D: focus on cardiorenal disease - Predisposing activity
    Clinical audit: An update on organ protection in T2D: focus on cardiorenal disease - Education
    Clinical audit: An update on organ protection in T2D: focus on cardiorenal disease - Audit introduction
    Clinical audit: An update on organ protection in T2D: focus on cardiorenal disease - Patient entry
    Clinical audit: An update on organ protection in T2D: focus on cardiorenal disease - Reflective activity
    Clinical audit: An update on organ protection in T2D: focus on cardiorenal disease - Reinforcing activity
    Clinical audit: An update on organ protection in T2D: focus on cardiorenal disease - Evaluation
    Sponsored by
    RACGP and ACRRM CPD logo